



This list of clinical research protocols relating to lung cancer is compiled for your convenience.

For more information on these protocols, please call PDQ, a service of the National Cancer Institute, at 1-800-4-CANCER. The PDQ Web site is accessible at http://www.cancer.gov/clinical_trials.

A searchable Web site developed by the National Library of Medicine is also available at <http://clinicaltrials.gov>.

SELECTED CLINICAL RESEARCH PROTOCOLS RELATING TO LUNG CANCER

Prevention

WSU-093201MP4F, WSU-D-2405 Phase II Study of Zileuton for the Prevention of Lung Cancer in Patients With Bronchial Dysplasia

Chairperson: Omer Kucuk, MD. Telephone: 313-745-2797; 800-527-6266. Lead organization: Barbara Ann Karmanos Cancer Institute. Age range: active 18 and over for patients with prior lung or head and neck cancer, 40 and over for all other patients.

E-5597, ACOSOG-E5597, CAN-NCIC-BR16, CLB-79803, NCCTG-E5597, NCI-P00-0176, SWOG-E5597 Phase III Randomized Chemoprevention Study of Selenium in Participants With Previously Resected Stage I Non-Small Cell Lung Cancer

Chairperson: Daniel David Karp, MD. Telephone: 617-667-1910. Lead organization: Eastern Cooperative Oncology Group. Age range: active 18 and over.

Screening

ACRIN-6654 Randomized Screening Study of Low-Dose Helical Computed Tomography Versus Radiography of the Chest in Participants at High Risk for Lung Cancer

Chairperson: Denise Aberle, MD. Telephone: 310-825-5268. Lead organization: American College of Radiology Imaging Network. Age range: 55 to 74.

NYU-9928, NCI-G01-1913 Screening and Diagnostic Study of Computerized Tomography in Women at High Risk for Lung Cancer

Chairperson: Abraham Chachoua, MD. Telephone: 212-263-6485. Lead organization: NYU School of Medicine's Kaplan Comprehensive Cancer Center. Age range: over 18.

Phase I

UPCC-NCI-5150, NCI-5150 Phase I Study of Paclitaxel and Carboplatin Followed by Tipifarnib Concurrently With Radiotherapy Followed by Maintenance Therapy With Tipifarnib in Patients With Stage IIIA or IIIB Non-Small Cell Lung Cancer

Chairperson: Stephen Michael Hahn, MD. Telephone: 215-662-7296. Lead organization: University of Pennsylvania Cancer Center. Age range: 18 and over.

Phase II/III

MAYO-MC0123, NCI-5641 Phase II Study of Tipifarnib, Gemcitabine, and Cisplatin in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer

Chairperson: Alex A. Adjei, MD, PhD. Telephone: 507-284-2511. Lead organization: Mayo Clinic Cancer Center. Age range: 18 and over.

CLB-9335, E-C9335 Phase II Study of Video-Assisted Thoracoscopic Wedge Resection (VAR) Followed by Radiotherapy in Patients With Stage I Non-Small Cell Lung Cancer and Cardiopulmonary Dysfunction

Chairperson: Hani Shennib, MD. Telephone: 514-937-6011, ext 4327. Lead organization: Cancer

and Leukemia Group B. Age range: 18 and over.

CLB-30106 Phase II Study of Paclitaxel, Carboplatin, and Gefitinib Followed by Radiotherapy With or Without Paclitaxel and Carboplatin Followed by Gefitinib in Patients With Stage III Non-Small Cell Lung Cancer

Chairperson: Neal Ready, MD. Telephone: 401-444-5391. Lead organization: Cancer and Leukemia Group B. Age range: 18 and over.

GENTA-GN304, NCI-G01-2046 Phase II/III Randomized Study of Docetaxel With or Without Oblimersen in Patients With Previously Treated Non-Small Cell Lung Cancer

Chairperson: Jennifer Lee. Telephone: 908-286-9800. Lead organization: Genta Incorporated. Age range: 18 and over.

E-4599, CLB-E-4599, CTSU Phase II/III Randomized Study of Paclitaxel and Carboplatin With or Without Bevacizumab in Patients With Advanced, Metastatic, or Recurrent Non-Squamous Cell Non-Small Cell Lung Cancer

Chairperson: Alan B. Sandler, MD. Telephone: 615-936-1782; 1-800-811-8480. Lead organization: Eastern Cooperative Oncology Group. Age range: active 18 and over.

Phase III

CAN-NCIC-BR19, CTSU, E-CAN-NCIC-BR19, SWOG-CAN-NCIC-BR19 Phase III Randomized Study of Adjuvant Gefitinib in Patients With Completely Resected

Primary Stage IB, II, or IIIA Non-Small Cell Lung Cancer

Chairperson: Glenwood Dillon Goss, MD, BCh, FCP, FRCPC. Telephone: 613-737-7700 ext. 6792. Lead organization: NCIC-Clinical Trials Group. Age range: active 18 and over.

CNR-NICO-01, EU-97010 Phase III Adjuvant Study of Cisplatin and Etoposide Combination for Stages I, II, and IIIA Non-Small Cell Lung Cancer

Chairperson: Antonio Nicolucci, MD. Telephone: 0872/578571. Lead organization: European Institute of Oncology - Chemo Prevention. Age range: 70 and under.

LIGAND-L1069-48, BMC-C-7093-49 Phase III Randomized Study of Carboplatin and Paclitaxel With Bexarotene Versus Carboplatin and Paclitaxel Alone in Patients With Chemotherapy-Naive Stage IIIB or IV Non-Small Cell Lung Cancer

Chairperson: Mack H. Mabry, MD. Telephone: 858-550-7518. Lead organization: Ligand Pharmaceuticals, Inc. Age range: not specified.

LIGAND-L1069-49 Phase III Randomized Study of Cisplatin and Vinorelbine With or Without Bexarotene in Patients With Chemotherapy-Naive Advanced or Metastatic Non-Small Cell Lung Cancer

Chairperson: Mack H. Mabry, MD. Telephone: 858-550-7518. Lead organization: Ligand Pharmaceuticals, Inc. Age range: any age

SWOG-S0023, CAN-NCIC-BR-15, CTSU, NCCTG-S0023 Phase III Randomized Study of Cisplatin,

Etoposide, Radiotherapy, and Docetaxel With or Without Gefitinib in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Chairperson: Karen Kelly, MD. Telephone: 303-315-8801; 800-473-2288. Lead organization: Southwest Oncology Group. Age range: not specified.

NCI NCCTG-N01C9, NCI-P02-0226 Phase III Randomized Study of Docetaxel With or Without Infliximab in Elderly and/or Poor Performance Status Patients With Wasting, Anorexia, and Asthenia Related to Unresectable Non-Small Cell Lung Cancer

Chairperson: Aminah Jatoui, MD. Telephone: 507-284-2511. Lead organization: North Central Cancer Treatment Group. Age range: adult.

RPCI-DS-01-17, ALPHA-A1-99002L Phase III Randomized Study of Gemcitabine and Carboplatin Versus Gemcitabine and Paclitaxel Versus Paclitaxel and Carboplatin in Patients With Stage IIIB or IV or Recurrent Non-Small Cell Lung Cancer

Chairperson: Nithya Ramnath, MD. Telephone: 716-845-4368; 1-800-767-9355. Lead organization: Roswell Park Cancer Institute. Age range: 18 and over.

MDA-ID-99303, NCCAM, NCI-T99-0046 Phase III Randomized Study of Induction Platinum-Based Chemotherapy and Radiotherapy With or Without AE-941 (Neovastat) in Patients With Unresectable Stage IIIA or IIIB Non-Small Cell Lung Cancer

Chairperson: Charles Lu, MD. Telephone: 713-792-6363; 800-392-

1611. Lead organization: University of Texas - MD Anderson Cancer Center. Age range: 18 and over.

ACOSOG-Z0030 Phase III Randomized Study of Mediastinal Lymph Node Sampling Versus Complete Lymphadenectomy During Pulmonary Resection in Patients with N0 or N1 (Less Than Hilar) Non-Small Cell Lung Cancer

Chairperson: Mark S. Allen, MD. Telephone: 507-284-2644. Lead organization: American College of Surgeons Oncology Group. Age range: 18 and over.

CLB-9633, CLB-C9633, CTSU, RTOG-9616 Phase III Randomized Study of Paclitaxel and Carboplatin Versus No Adjuvant Chemotherapy After Resection in Patients With Stage IB Non-Small Cell Lung Cancer

Chairperson: Gary M. Strauss, MD. Telephone: 617-632-2130. Lead organization: Cancer and Leukemia Group B. Age range: 18 and over.

CTI-PGT303 Phase III Randomized Study of Polyglutamate Paclitaxel (CT-2103) and Carboplatin Versus Paclitaxel and Carboplatin in Patients With Chemotherapy-Naive Stage IIIB or IV or Recurrent Non-Small Cell Lung Cancer Who Have a Performance Status of 2

Chairperson: Lee King, MA. Telephone: 910-772-6906. Lead organization: Cell Therapeutics, Inc. Age range: 18 and over.

CTI-PGT302 Phase III Randomized Study of Polyglutamate Paclitaxel (CT-2103) Versus Docetaxel as Second-Line Therapy in Patients With Progressive Non-Small Cell Lung Cancer

Chairperson: Brenda Garrison. Telephone: 910-772-6952. Lead organization: Cell Therapeutics, Inc. Age range: 18 and over.

CTI-PGT304 Phase III Randomized Study of Polyglutamate Paclitaxel (CT-2103) Versus Gemcitabine or Vinorelbine in Patients With Chemotherapy-Naive Stage IIIB or IV or Recurrent Non-Small Cell Lung Cancer Who Have a Performance Status of 2

Chairperson: Lee King, MA. Telephone: 910-772-6906. Lead organization: Cell Therapeutics, Inc. Age range: 18 and over.

RTOG-0214, E-RTOG-0214 Phase III Randomized Study of Prophylactic Cranial Irradiation in Patients With Stage IIIA or IIIB Non-Small Cell Lung Cancer

Chairperson: Elizabeth M. Gore, MD. Telephone: 414-805-4465. Lead organization: Radiation Therapy Oncology Group. Age range: 18 and over.

SWOG-S0002, CLB-79807, E-S0002, NCI-P02-0215 Phase III Randomized Study of Smoking Cessation Intervention With or Without Bupropion in Patients With Completely Resected Stage I or II Non-Small Cell Lung Cancer Who are Current Smokers

Chairperson: Ellen R. Gritz, PhD. Telephone: 713-745-3187; 800-392-1611. Lead organization: Southwest Oncology Group. Age range: 18 and over.

SWOG-S9900, CTSU, E-S9900, NCCTG-S9900, RTOG-L0015 Phase III Randomized Study of Surgery With or Without Preop-

erative Paclitaxel and Carboplatin in Patients With Stage IB, II, or Selected IIIA Non-Small Cell Lung Cancer

Chairperson: Paul A. Bunn, MD. Telephone: 303-315-3007; 800-473-2288. Lead organization: Southwest Oncology Group. Age range: 18 and over.